- Conditions
- Peripheral Arterial Disease
- Interventions
- Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
- Drug · Behavioral · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 27,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- MEDI3414 [Influenza A/H1N1 live attenuated, intranasal], Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Daytona Beach, Florida • Miami, Florida • South Miami, Florida + 2 more
- Conditions
- Nicotine Dependence, Major Depressive Disorder
- Interventions
- Varenicline, BASC, Standard treatment
- Drug · Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- Placebo, QBW251
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Atrophic Vaginitis
- Interventions
- Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 30 Years to 75 Years · Female only
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
- Conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Interventions
- ABT-335, placebo, atorvastatin, ezetimibe
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 118
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
- Conditions
- Neonatal Staphylococcal Sepsis
- Interventions
- Pagibaximab (formerly BSYX-A110)
- Drug
- Lead sponsor
- Biosynexus Incorporated
- Industry
- Eligibility
- 3 Days to 7 Days
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Interventions
- pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 19
- States / cities
- Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
- Conditions
- Healthy Subjects
- Interventions
- STP707
- Drug
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- CHF 4226 pMDI, Placebo
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- DeLand, Florida • Madisonville, Kentucky • Cincinnati, Ohio + 2 more
- Conditions
- Binocular Dysfunction, Vertical Heterophoria, Vision, Binocular, Vision Disparity
- Interventions
- Lenses containing prismatic correction, Lenses not containing prismatic correction
- Device
- Lead sponsor
- Vision Specialists of Birmingham
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Michigan
- Conditions
- Xerostomia, Sjogren's Syndrome
- Interventions
- P-552, Placebo
- Drug
- Lead sponsor
- Parion Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Interventions
- R932333, Placebo
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Patellofemoral realigning knee brace, Non-aligning knee brace
- Device
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse
- Interventions
- Divalproex Sodium, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Subjective Tinnitus
- Interventions
- OTO-313, Placebo
- Drug
- Lead sponsor
- Otonomy, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 31
- States / cities
- Fresno, California • Torrance, California • Aurora, Colorado + 26 more
- Conditions
- Tumors
- Interventions
- NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
- Drug
- Lead sponsor
- Nina Bhardwaj
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Subjects
- Interventions
- TAVO103A, Placebo
- Drug · Other
- Lead sponsor
- Tavotek Biotherapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Uveitis
- Interventions
- Izokibep, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Hypercholesterolemia
- Interventions
- AVE5530, atorvastatin, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Complex Regional Pain Syndrome Type I
- Interventions
- Neridronate, Placebo
- Drug
- Lead sponsor
- Ambros Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 32 more
- Conditions
- Cardiovascular Diseases in Old Age, Aging, Cardiovascular Diseases, Sleep
- Interventions
- Ketone Ester, Placebo
- Dietary Supplement
- Lead sponsor
- Georgia Southern University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost eye drops, placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia